Drug Profile
Spesolimab - Boehringer Ingelheim
Alternative Names: BI 655130; Spesolimab-sbzo; SPEVIGOLatest Information Update: 25 Mar 2024
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Anti-inflammatories; Antipsoriatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin 36 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Generalised pustular psoriasis
- Phase II/III Hidradenitis suppurativa; Netherton Syndrome; Ulcerative colitis
- Phase II Crohn's disease; Palmoplantar pustulosis
- Discontinued Atopic dermatitis
Most Recent Events
- 19 Mar 2024 Launched for Generalised pustular psoriasis (In adolescents, In children) in USA (IV)
- 19 Mar 2024 Preregistration for Generalised pustular psoriasis (In adolescents, In adults, In children) in China (IV) prior to March 2024
- 19 Mar 2024 Registered for Generalised pustular psoriasis (In adolescents, In children) in USA (IV)